Johnson & Johnson to Take $4 Billion Hit

Posted on 11/15/2013 by |Legal Grounds | Comments

Bulletin TodayRecently I wrote about how Johnson & Johnson inappropriately marketed Risperdal to treat agitation, confusion and other symptoms in older patients with dementia. As if that’s not enough, the company’s now tentatively agreeing to a $4 billion — yes, that’s billion — settlement with thousands of patients for whom a company-made hip implant failed. As the New York Times described it this week, J & J’s Depuy Orthapaedics unit made and marketed its Articular Surface Replacement, an all-metal hip implant, to doctors …